These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 31519183)
1. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183 [TBL] [Abstract][Full Text] [Related]
2. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504 [TBL] [Abstract][Full Text] [Related]
3. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer]. Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313 [No Abstract] [Full Text] [Related]
4. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421 [TBL] [Abstract][Full Text] [Related]
5. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049 [TBL] [Abstract][Full Text] [Related]
6. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter? Markauskas A; Mogensen O; dePont Christensen R; Jensen PT Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461 [TBL] [Abstract][Full Text] [Related]
7. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer. Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536 [TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis. Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843 [TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Luo Y; Lee M; Kim HS; Chung HH; Song YS Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269 [TBL] [Abstract][Full Text] [Related]
11. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Coleridge SL; Bryant A; Kehoe S; Morrison J Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210 [TBL] [Abstract][Full Text] [Related]
13. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer. Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533 [TBL] [Abstract][Full Text] [Related]
14. The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery. Yang SP; Chen JX; Xu JY; Lei J; Wu SG; Zhou J Cancer Med; 2022 Jul; 11(14):2836-2845. PubMed ID: 35274489 [TBL] [Abstract][Full Text] [Related]
15. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients. Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466 [TBL] [Abstract][Full Text] [Related]
16. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. Wang D; Zhang G; Peng C; Shi Y; Shi X J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198 [TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850). Marchetti C; Giannarelli D; Vizzielli G; Ferrandina G; Tortorella L; Fanfani F; Costantini B; Pasciuto T; Scambia G; Fagotti A BJOG; 2023 Dec; 130(13):1579-1588. PubMed ID: 37334772 [TBL] [Abstract][Full Text] [Related]
18. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study. Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565 [TBL] [Abstract][Full Text] [Related]
19. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. Filippova OT; Boecking K; Broach V; Gardner GJ; Sonoda Y; Chi DS; Zivanovic O; Long Roche K Gynecol Oncol; 2024 Aug; 187():80-84. PubMed ID: 38735143 [TBL] [Abstract][Full Text] [Related]
20. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer. Lee J; Curtin JP; Muggia FM; Pothuri B; Boyd LR; Blank SV Cancer Chemother Pharmacol; 2018 Jul; 82(1):55-63. PubMed ID: 29704010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]